Adjudicada
suministro de diversos medicamentos exclusivos con destino a los centros sanitarios dependientes de la Gerencia Regional de Salud de Castilla y León
Gerencia Regional de Salud de Castilla y León
- Importe adjudicado56.851.104 €
- Plazo de presentación15/07/2024
- LocalizaciónVALLADOLID
- ProcedimientoNegociado con publicidad
- CPV33652100 (+7)
- Obras
Fechas clave
- Fin de plazo de presentación15/07/2024
- Anuncio de licitación19/09/2024
- Adjudicación19/09/2024
- Hoy26/07/2026
Datos del contrato
- Expediente
- 2020014604
- Dependiente de
- Castilla y León › COMUNIDADES Y CIUDADES AUTÓNOMAS › Sector Público
- Valor estimado
- 439.739.764 €
- Código NUTS
- ES418
- Tramitación
- Ordinaria
- Método de presentación
- Electrónica
Lotes
| Lote | Título | Importe |
|---|---|---|
| 1 | Risankizumab | 2.285.487 € |
| 10 | Niraparib | 2.220.560 € |
| 11 | belimumab | 1.104.710 € |
| 12 | Abemaciclib | 2.223.656 € |
| 13 | ramucirumab | 1.788.377 € |
| 14 | galcanezumab | 673.400 € |
| 15 | riociguat | 1.474.824 € |
| 16 | raltegravir | 915.727 € |
| 17 | cetuximab | 2.888.445 € |
| 18 | avelumab | 1.391.156 € |
| 19 | eltrombopag | 3.704.678 € |
| 2 | Levodopa e inhibidor de la decarboxilasa | 2.223.271 € |
| 20 | nilotinib | 2.308.680 € |
| 21 | Dabrafenib | 1.318.956 € |
| 22 | Ribociclib | 3.744.934 € |
| 23 | Ruxolitinib | 3.896.369 € |
| 24 | Alpelisib | 987.438 € |
| 25 | Canakinumab | 1.053.113 € |
| 26 | Isavuconazol | 1.519.707 € |
| 27 | Obinutuzumab | 1.041.694 € |
| 28 | Pertuzumab | 5.715.094 € |
| 29 | Laronidase | 931.856 € |
| 3 | Dexametasona oftálmica | 7.257.983 € |
| 30 | Eliglustat | 1.158.830 € |
| 31 | Isatuximab | 904.447 € |
| 32 | Certolizumab | 1.631.626 € |
| 33 | Abatacept | 3.029.672 € |
| 34 | Clevidipino | 911.588 € |
| 35 | Amfotericina B liposomal | 1.647.397 € |
| 36 | Emtricitabina, tenofovir alafenamida y bictegravir | 6.593.920 € |
| 37 | Sacituzumab govitecan | 1.197.912 € |
| 38 | Darolutamida | 758.922 € |
| 39 | Dolutegravir | 1.761.181 € |
| 4 | Romiplostim | 2.022.584 € |
| 40 | Dolutegravir y Rilpivirina | 1.895.227 € |
| 41 | Lamivudina Y Dolutegravir | 5.183.566 € |
| 42 | Selexipag | 2.002.088 € |
| 43 | Macitentan | 2.049.608 € |
| 44 | Darunavir y Cobicistat | 706.957 € |
| 45 | Ibrutinib | 11.160.974 € |
| 46 | Apalutamida | 4.322.757 € |
| 47 | Guselkumab | 3.772.461 € |
| 48 | Agalsidasa Alfa | 1.054.274 € |
| 49 | Idursulfasa | 3.026.054 € |
| 5 | Etelcalcetida | 949.331 € |
| 50 | Vedolizumab | 5.711.506 € |
| 51 | Nintedanib | 283.428 € |
| 52 | Lenvatinib | 991.635 € |
| 53 | Enzalutamida | 6.113.193 € |
| 54 | Patisiran | 772.910 € |
| 55 | Trifluridina | 1.520.900 € |
| 6 | Panitumumab | 2.644.042 € |
| 7 | Carfilzomib | 1.466.559 € |
| 8 | Osimertinib | 6.628.685 € |
| 9 | Acalabrutinib | 1.738.597 € |
Adjudicatarios
| Lote | Adjudicatario | Importe | Fecha |
|---|---|---|---|
| ASTRAZENECA FARMACEUTICA SPAIN, S.A | 6.628.685 € | 19/09/2024 | |
| GILEAD SCIENCES,SL | 6.593.920 € | 19/09/2024 | |
| ASTELLAS PHARMA, SA | 5.847.402 € | 19/09/2024 | |
| LABORATORIOS VIIV HEALTHCARE, SL | 5.183.566 € | 19/09/2024 | |
| NOVARTIS FARMACÉUTICA, SA | 3.744.922 € | 19/09/2024 | |
| BRISTOL-MYERS SQUIBB, SAU | 3.029.664 € | 19/09/2024 | |
| MERCK, S.L.U. | 2.888.445 € | 19/09/2024 | |
| Persona física | 2.644.042 € | 19/09/2024 | |
| ABBVIE SPAIN, SLU | 2.285.481 € | 19/09/2024 | |
| LILLY, S.A. | 2.112.471 € | 19/09/2024 | |
| AMGEN, SA | 2.022.584 € | 19/09/2024 | |
| JANSSEN-CILAG, SA | 2.002.088 € | 19/09/2024 | |
| UCB PHARMA,SA | 1.569.712 € | 19/09/2024 | |
| PFIZER SL | 1.519.700 € | 19/09/2024 | |
| MERCK SHARP & DOHME DE ESPAÑA, SA | 1.474.824 € | 19/09/2024 | |
| GLAXOSMITHKLINE, S.A | 1.104.710 € | 19/09/2024 | |
| ROCHE FARMA, SA | 1.041.694 € | 19/09/2024 | |
| TAKEDA FARMACÉUTICA ESPAÑA, SA | 975.200 € | 19/09/2024 | |
| SANOFI-AVENTIS, SA | 931.856 € | 19/09/2024 | |
| FERRER FARMA, S.A. | 911.588 € | 19/09/2024 | |
| ALNYLAM PHARMACEUTICALS SPAIN, S.L | 772.910 € | 19/09/2024 | |
| BAYER HISPANIA, SL | 659.932 € | 19/09/2024 | |
| ORGANON SALUD SL. | 622.280 € | 19/09/2024 | |
| BOEHRINGER INGELHEIM ESPAÑA, SA | 283.428 € | 19/09/2024 | |
| Sin adjudicatario | 19/09/2024 |